Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers

Per Hydbring, Yinan Wang, Anne Fassl, Xiaoting Li, Veronica Matia, Tobias Otto, Yoon Jong Choi, Katharine E. Sweeney, Jan M. Suski, Hao Yin, Roman L. Bogorad, Shom Goel, Haluk Yuzugullu, Kevin J. Kauffman, Junghoon Yang, Chong Jin, Yingxiang Li, Davide Floris, Richard Swanson, Kimmie NgEwa Sicinska, Lars Anders, Jean J. Zhao, Kornelia Polyak, Daniel G. Anderson, Cheng Li, Piotr Sicinski

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


Cyclins and cyclin-dependent kinases (CDKs) are hyperactivated in numerous human tumors. To identify means of interfering with cyclins/CDKs, we performed nine genome-wide screens for human microRNAs (miRNAs) directly regulating cell-cycle proteins. We uncovered a distinct class of miRNAs that target nearly all cyclins/CDKs, which are very effective in inhibiting cancer cell proliferation. By profiling the response of over 120 human cancer cell lines, we derived an expression-based algorithm that can predict the response of tumors to cell-cycle-targeting miRNAs. Using systemic administration of nanoparticle-formulated miRNAs, we inhibited tumor progression in seven mouse xenograft models, including three treatment-refractory patient-derived tumors, without affecting normal tissues. Our results highlight the utility of using cell-cycle-targeting miRNAs for treatment of refractory cancer types.

Original languageEnglish (US)
Pages (from-to)576-590.e8
JournalCancer Cell
Issue number4
StatePublished - Apr 10 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • cancers
  • cell cycle
  • cyclin-dependent kinases
  • cyclins
  • microRNAs


Dive into the research topics of 'Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers'. Together they form a unique fingerprint.

Cite this